background: The Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial was a randomized, double-blind study of a fixed-dose regimen of apixaban versus conventional therapy (enoxaparin/warfarin) for 6 months in patients with acute venous thromboembolism (VTE). The AMPLIFY trial demonstrated that apixaban was noninferior to conventional therapy in preventing recurrent symptomatic VTE or death related to VTE and was associated with significantly less major bleeding and clinically relevant non-major bleeding. This analysis evaluated the effects of apixaban versus conventional therapy on all-cause hospitalizations during the AMPLIFY trial.
